8.00

1.11% -0.09

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $8.00, with a volume of 938.05K. It is down -1.11% in the last 24 hours and down -2.44% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Previous Close:

$8.09

Open:

$8.18

24h Volume:

938.05K

Relative Volume:

0.63

Market Cap:

$883.69M

Revenue:

Net Income/Loss:

$-242.30M

P/E Ratio:

-3.2258

EPS:

-2.48

Net Cash Flow:

$-192.10M

1W Performance:

-0.37%

1M Performance:

-2.44%

6M Performance:

-21.88%

1Y Performance:

-6.54%

1-Day Range:

$7.89

$8.23

1-Week Range:

$7.88

$8.285

52-Week Range:

$5.73

$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

164

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT Cogent Biosciences Inc	8.00	883.69M	0	-242.30M	-192.10M	-2.48
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

02:47 AM

Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat

Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World

Feb 11, 2025

Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Feb 11, 2025

Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Feb 11, 2025

FY2025 Earnings Estimate for COGT Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.33 Consensus PT from Brokerages - Defense World

Feb 11, 2025

Cogent Biosciences Announces Bezuclastinib Poster in - GlobeNewswire

Feb 11, 2025

Feb 10, 2025

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - The Manila Times

Feb 10, 2025

Cogent Biosciences to Present Long-Term Efficacy Results of Bezuclastinib at AAAAI Annual Meeting 2025 - Nasdaq

Feb 10, 2025

Cogent's NonAdvSM Treatment Shows Long-Term Patient BenefitsKey Data Coming at AAAAI 2025 - StockTitan

Feb 10, 2025

Feb 09, 2025

One Cogent Biosciences Insider Raised Stake By 2,085% In Previous Year - Simply Wall St

Feb 09, 2025

Feb 08, 2025

Analysts Issue Forecasts for COGT Q1 Earnings - Defense World

Feb 08, 2025

Feb 07, 2025